FDA Grants Priority Review to Nivolumab Plus Ipilimumab to Treat NSCLC

Bristol Myers Squibb recently announced that the FDA granted priority review to nivolumab plus ipilimumab in combination with chemotherapy as a first-line treatment for metastatic NSCLC.

Source: CancerNetwork - April 8, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news